<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266408</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2010_02</org_study_id>
    <nct_id>NCT01266408</nct_id>
  </id_info>
  <brief_title>INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)</brief_title>
  <official_title>International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the risks of short- and long-term use of contraceptives containing
      drospirenone (DRSP) or dienogest (DNG)/ethinylestradiol (EE) plus levomefolate calcium
      (metafolin) with the risks of short- and long-term use of other established oral
      contraceptives (OCs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New oral contraceptives (OCs) containing drospirenone (DRSP) or dienogest
      (DNG)/ethinylestradiol (EE) plus levomefolate calcium (metafolin) have been recently
      introduced and will be introduced in a number of countries in the near future. Although the
      safety of OCs has improved over the last 50 years with reductions in the estrogen and
      progestogen dose, special attention regarding oral contraceptive safety amongst women with
      risk factors for venous and arterial thromboembolism as well as cancer is necessary. Folic
      acid supplementation has been implicated in both the prevention and the promotion of several
      cancers, including colorectal cancer (CRC). Chronic folate deficiency seems to be associated
      with colorectal carcinogenesis, while high folic acid levels may have a tumor-promoting
      effect. On balance an oral contraceptive containing folate may be advantageous for several
      reasons. It may increase baseline folate levels with potential for protecting against some
      malignancies and concurrently decrease the risk of neural tube defects in women who become
      pregnant due to OC-failure, incorrect OC-use or after stopping the OC for a planned
      pregnancy. Although unexpected, it is unclear whether combined oral contraceptives plus
      metafolin in general and specifically DRSP/EE plus metafolin and DNG/EE plus metafolin will
      alter the risk profile of established oral contraceptives.

      This study investigates the safety of these new oral contraceptives with regard to
      cardiovascular outcomes and colorectal cancer.

      INAS-FOCUS is a prospective, controlled, non-interventional cohort study with three study
      arms: users of DRSP/EE/metafolin, users of DNG/EE/metafolin and users of OCs containing other
      estrogen/progestogen combinations. The users will be grouped to starters (first-ever users),
      switchers (women switching OC without a pill intake break) and restarters (women with a pill
      intake break). Users of an OC are accrued by a network of prescribing physicians. Baseline
      and follow-up information is collected via a self-administered questionnaire. Data analysis
      will be based on life-table methods comparing the cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>Within 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer</measure>
    <time_frame>Within 15 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80000</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>DRSP/EE/metafolin</arm_group_label>
    <description>Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DNG/EE/metafolin</arm_group_label>
    <description>Women using oral contraceptives containing dienogest, ethinylestradiol and metafolin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other OC users</arm_group_label>
    <description>Women using oral contraceptives containing other estrogen/progestogen combinations</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women using oral contraceptives
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women starting OC use (&quot;starters&quot;)

          -  Women switching OC use without a pill intake break (&quot;switchers&quot;)

          -  Women restarting OC use after a pill intake break (&quot;restarters&quot;)

          -  Women willing to participate in the active surveillance

        Exclusion Criteria:

          -  Long-term users

          -  Women who do not agree to participate

          -  Women with a language barrier
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen C Dinger, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzanne Reed, MSc, PhD</last_name>
    <phone>+49 30 945 101 63</phone>
    <email>reed@zeg-berlin.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klaas Heinemann, PhD, MD, MBA</last_name>
    <phone>+49 30 945 101 24</phone>
    <email>k.heinemann@zeg-berlin.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Reed, MSc, PhD</last_name>
      <phone>+49 30 945 101 63</phone>
      <email>reed@zeg-berlin.de</email>
    </contact>
    <contact_backup>
      <last_name>Klaas Heinemann, PhD, MD, MBA</last_name>
      <phone>+49 30 945 101 24</phone>
      <email>k.heinemann@zeg-berlin.de</email>
    </contact_backup>
    <investigator>
      <last_name>Juergen C Dinger, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Juergen Dinger, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drospirenone</keyword>
  <keyword>Dienogest</keyword>
  <keyword>Metafolin</keyword>
  <keyword>Folic acid</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

